PharmacoEconomics

, Volume 30, Issue 8, pp 681–695

The Impact of Rotavirus Vaccination on Discounted Net Tax Revenue in Egypt

A Government Perspective Analysis
  • Mark P. Connolly
  • Oleksandr Topachevskyi
  • Baudouin Standaert
  • Omayra Ortega
  • Maarten Postma
Original Research Article

Abstract

Background

We evaluated national rotavirus (RV) immunization programme costs to estimate how resulting changes in morbidity and mortality will influence government fiscal accounts over time. The assumption was that increased childhood survival in vaccinated cohorts leads to increased numbers of children consuming government resource, and an increased number of future tax payers.

Objective

Our objective was to evaluate the difference in lifetime discounted net tax revenue generated by RV vaccinated and unvaccinated cohorts from the Egyptian government perspective.

Methods

The model framework adopts the Egyptian government perspective for RV immunization costs (year 2009 values) and all government transfers (e.g. education costs, health costs, pensions). To reflect the government tax revenue, we applied a fixed income tax burden to earnings over the lifetime of vaccinated and unvaccinated cohorts. At each year of the model, we derive net taxes (gross taxes less transfers) discounted to the immunization year to reflect the present value of RV vaccination investment costs.

Results

Projected incremental net present values of the vaccinated cohort versus the unvaccinated cohort are $US6.1 million, $US58.1 million and $US55.7 million at 25-, 50- and 72-year time horizons, respectively. The internal rate of return for the government based on RV vaccination at years 25, 50 and 72 was 10.8%, 15.1% and 14.9, respectively. Within the first 5 years of vaccination, 76% of vaccine acquisition costs were offset due to direct and indirect cost savings attributed to a reduction in RV-related disease burden. Investments in RV vaccination in a single year are entirely offset when the vaccinated cohort of newborns reach 22 years of age.

Conclusion

The government perspective is useful for evaluating investments in RV vaccination because of ongoing government transfers and tax receipts attributed to changes in RV-attributed morbidity and mortality. The analysis described here illustrates that investing in RV offers tangible long-term fiscal benefits for government over many generations that would not ordinarily be captured in economic evaluations typically applied to healthcare interventions.

References

  1. 1.
    Bloom DE, Canning D, Weston M. The value of vaccination. World Econ 2005; 6(3): 15–39Google Scholar
  2. 2.
    Bloom D, Canning D. Health as human capital and its impact on economic performance. Geneva Pap Risk Ins 2003; 28(2): 304–15CrossRefGoogle Scholar
  3. 3.
    WHO Commission on Macroeconomics and Health. Health, economic growth and poverty reduction: the report of Working Group I of the Commission on Macroeconomics and Health. Geneva: World Health Organization, 2002Google Scholar
  4. 4.
    Ehreth J. The global value of vaccination. Vaccine 2003 Oct; 21: 596–600PubMedCrossRefGoogle Scholar
  5. 5.
    World Health Organization. WHO model list of essential medicines. 16th rev. list. Geneva: WHO, 2010 MarGoogle Scholar
  6. 6.
    Contoyannis P, Rice N. The impact of health on wages: evidence from the British Household Panel Survey. Empirical Econ 2001; 26(4): 599–622CrossRefGoogle Scholar
  7. 7.
    World Health Organisation. WHO guide to identifying the economic consequences of disease and injury. Geneva: WHO, 2009Google Scholar
  8. 8.
    Sancak C, Velloso R, Xing J. Tax revenue response to the business cycle [IMF working paper no. WP/10/71]. Washington, DC: IMF, 2010 MarGoogle Scholar
  9. 9.
    Suhrcke M, McKee M, Arce RS, et al. The contribution of health to the economy in the European Union. Luxembourg: Office for Official Publications of the European Communities, 2005Google Scholar
  10. 10.
    Zentner A, Valasco-Garrido M, Busse R. Methods for the comparative evaluation of pharmaceuticals. GMS Health Technol Assess 2005; 1: Doc09PubMedGoogle Scholar
  11. 11.
    National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal [publication no. N0515]. London: NICE, 2004 AprGoogle Scholar
  12. 12.
    Bärnighausen T, Bloom DE, Canning D, et al. Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type b vaccine. Vaccine 2011; 29(13): 2371–80PubMedCrossRefGoogle Scholar
  13. 13.
    Standaert B, Harlin O, Desselberger U. The financial burden of rotavirus disease in four countries of the European Union. Pediatr Infect Dis J 2008; 27(1): S20–7Google Scholar
  14. 14.
    Gleizes O, Desselberger U, Tatochenko V, et al. Nosocomial rotavirus infection in European Countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease. Pediatr Infect Dis J 2006 Jan; 25(1): S12–21PubMedCrossRefGoogle Scholar
  15. 15.
    Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003 May; 9(5): 565–72PubMedCrossRefGoogle Scholar
  16. 16.
    Ortega O, El-Sayed N, Sanders JW, et al. Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt. J Infect Dis 2009 Nov; 200(1): S92–8PubMedCrossRefGoogle Scholar
  17. 17.
    Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the IS-POR Task Force on Good Research Practices — budget impact analysis. Value Health 2007 Sep–Oct; 10: 336–47PubMedCrossRefGoogle Scholar
  18. 18.
    Bonin H, Patxot C. Generational accounting as a tool to assess fiscal sustainability: an overview of the methodology [discussion paper no. 990]. Bonn: Institute for the Study of Labor, 2004 JanGoogle Scholar
  19. 19.
    Rice DP, Cooper BS. The economic value of human life. Am J Public Health Nations Health 1967 Nov; 57(11): 1954–66PubMedCrossRefGoogle Scholar
  20. 20.
    CAPMAS. Quarterly labor force sample survey: labor force, employment and unemployment in Egypt [online]. Available from URL: http://www.capmas.gov.eg/?lang=2 [Accessed 2012 May 15]
  21. 21.
    WHO. Egyptian life tables 2009 [online]. Available from URL: http://www.who.int/healthinfo/statistics/mortality_life_tables/en/ [Accessed 2010 Nov 23]
  22. 22.
    Rose J, Hawthorn RL, Watts B, et al. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. BMJ 2009 Sep; 339: b3653PubMedCrossRefGoogle Scholar
  23. 23.
    de Soárez PC, Valentim J, Sartori AMC, et al. Cost-effectiveness analysis of routine rotavirus vaccination in Brazil. Rev Panam Salud Publica 2008 Apr; 23(4): 221–30PubMedCrossRefGoogle Scholar
  24. 24.
    Widdowson MA, Meltzer MI, Zhang X, et al. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007 Apr; 119(4): 684–97PubMedCrossRefGoogle Scholar
  25. 25.
    CAPMAS. Annual bulletin for employment, wages, and work hours statistics [online]. Available from URL: http://www.capmas.gov.eg/news.aspx?lang=2&nid=552 [Accessed 2012 May 15]
  26. 26.
    International Organization of Pension Supervisors. IOPS country profile: Egypt [online]. Available from URL: http://www.iopsweb.org/dataoecd/32/11/42952582.pdf [Accessed 2012 May 12]
  27. 27.
    Ministry of Finance. The income tax law no. 91 of 2005 [online]. Available from URL: http://www.mof.gov.eg/MOFGallerySource/english/IncomeTaxLaw.pdf [Accessed 2010 Aug 18]
  28. 28.
    World Bank. Labor and social protection [online]. Available from URL: http://data.worldbank.org/topic/labor-and-social-protection [Accessed 2011 Jul 29]
  29. 29.
    Central Intelligence Agency. The world factbook: Egypt, 2011 [online]. Available from URL: https://www.cia.gov/library/publications/the-world-factbook/geos/eg.html [Accessed 2011 Feb 15]
  30. 30.
    Linhares A, Valzquez FR, Perez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomized, double blind, placebo-controlled phase III study. Lancet 2008; 371(9619): 1181–9PubMedCrossRefGoogle Scholar
  31. 31.
    Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370(9601): 1757–63PubMedCrossRefGoogle Scholar
  32. 32.
    Flannery B. How have rotavirus vaccines worked in developing countries in Latin America? 9th International Rotavirus Symposium; 2010 Aug 2–3; Johannesburg [online]. Available from URL: http://www.sabin.org/files/uploads/B%20Flannery.pdf [Accessed 2011 Jul 29]
  33. 33.
    Naficy AB, Abu-Elyazeed R, Holmes JL, et al. Epidemiology of rotavirus diarrhea in Egyptian children and implications for disease control. Am J Epidemiol 1999; 150: 770–7PubMedCrossRefGoogle Scholar
  34. 34.
    Parashar UD, Bresee JS, Geuntsch JR, et al. Rotavirus. Emerg Infect Dis 1998 Oct–Dec; 4(4): 561–70PubMedCrossRefGoogle Scholar
  35. 35.
    Gianino P, Mastretta E, Longo P, et al. Incidence of nosocomial rotavirus infections, symptomatic and asymptomatic, in breast-fed and non-breast-fed infants. J Hosp Infect 2002 Jan; 50(1): 13–7PubMedCrossRefGoogle Scholar
  36. 36.
    Dennehy PH, Cortese MM, Begue RE, et al. A case-control study to determine risk factors for hospitalization for rotavirus gastroenteritis in U.S. children. Pediatr Infect Dis J 2006; 25(12): 1123–31CrossRefGoogle Scholar
  37. 37.
    Morris SS, Black RE, Tomaskovic L. Predicting the distribution of under-five deaths by cause in countries without adequate vital registration systems. Int J Epidemiol 2003 Dec; 32: 1041–51PubMedCrossRefGoogle Scholar
  38. 38.
    World Bank. Health expenditure per capita (current US$) [online]. Available from URL: http://data.worldbank.org/indicator/SH.XPD.PCAP [Accessed 2011 Jul 29]
  39. 39.
    El-Zanaty F, Way A. Egypt demographic and health survey 2008 [online]. Available from URL: http://www.measuredhs.com/pubs/pdf/FR220/FR220.pdf [Accessed 2011 Jul 30]
  40. 40.
    World Bank. World development indicators 2005 [online]. Available from URL: http://data.worldbank.org/data-catalog/world-development-indicators [Accessed 2011 Jul 30]
  41. 41.
    The Egyptian-British Chamber of Commerce. Tax policies in Egypt [online]. Available from URL: http://www.theebcc.com/files/EBCC%20Report%20-%20Tax%20Policies%20in%20Egypt.doc [Accessed 2011 Aug 10]
  42. 42.
    Feist K. Generational accounting as a tool for modelling social expenditure in Europe. Futures 2003 Feb; 35(1): 49–59CrossRefGoogle Scholar
  43. 43.
    Prušvic D, Pavlokova K. Generational accounting in European health care systems. Czech J Econ Finance 2010; 60(5): 378–99Google Scholar
  44. 44.
    OECD. Education at a glance 2008. Paris: OECD, 2008 SepGoogle Scholar
  45. 45.
    Acemoglu D, Johnson S. Disease and development: the effect of life expectancy on economic growth. J Polit Econ 2007; 115(6): 925–85CrossRefGoogle Scholar
  46. 46.
    Connolly M, Pollard MS, Hoorens S, et al. Long-term economic benefits attributed to IVF conceived children: a lifetime tax calculation. Am J Manag Care 2008 Sep; 14(9): 598–604PubMedGoogle Scholar
  47. 47.
    Directorate-General for Economic and Financial Affairs, European Commission. Sustainability report 2009: European economy 9. Luxembourg: Office for Official Publications of the European Communities, 2009Google Scholar
  48. 48.
    Brown J, Buxton M. The economic perspective. Br Med Bull 1998; 54(4): 993–1009PubMedCrossRefGoogle Scholar
  49. 49.
    Schael IP, González R, Salinas B. Severity and age of rotavirus diarrhea, but not socioeconomic conditions, are associated with rotavirus seasonality in Venezuela. J Med Virol 2009 Mar; 81(3): 562–7PubMedCrossRefGoogle Scholar
  50. 50.
    Kurugöl Z, Geylani S, Karaca Y, et al. Rotavirus gastroenteritis among children under five years of age in Izmir, Turkey. Turk J Pediatr 2003 Oct–Dec; 45(4): 290–4PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Mark P. Connolly
    • 1
    • 2
  • Oleksandr Topachevskyi
    • 3
  • Baudouin Standaert
    • 3
  • Omayra Ortega
    • 4
  • Maarten Postma
    • 1
  1. 1.PharmacoEpidemiology and PharmacoEconomics, Department of PharmacyUniversity of GroningenGroningenThe Netherlands
  2. 2.Global Market Access SolutionsSaint-PrexSwitzerland
  3. 3.GlaxoSmithKline BiologicalsWavreBelgium
  4. 4.Department of Mathematical and Natural SciencesArizona State UniversityPhoenixUSA

Personalised recommendations